证券代码：688468 证券简称：科美诊断 公告编号：2025-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科美诊断技术股份有限公司（以下简称"公司"）第二届董事会第十三次 会议于2025年4月27日以现场结合通讯方式召开，本次会议通知于2025年4月17日 以电子邮件方式送达公司全体董事。本次会议由董事长李临先生召集并主持，应 出席的董事9人，实际出席的董事9人。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》等法律、法规及《科美诊断技术股份有限公司章程》 《科美诊断技术股份有限公司董事会议事规则》的有关规定。 经与会董事认真讨论，审议通过如下事项： （一）审议通过《公司2024年年度报告及其摘要》 表决结果：9票同意；0票反对；0票弃权。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《科美诊断技术股份有限公司2024年年度报告》及《科美诊断技术股份有限公 司2024年年度报告摘要》。 本议案已经公司第二届董事会审计委员会第十一次会议审议通过；公司财 务报表已经 ...

证券代码：688468 证券简称：科美诊断 公告编号：2025-004 每股分配比例：每10股派发人民币1.25元（含税）。不进行资本公积金 转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣除回购专户 中的股份数为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整利润分配总额，并将另行公告具体调整情况。 公司不会触及《上海证券交易所科创板股票上市规则（2024年4月修订） 》（以下简称"《科创板股票上市规则》"）第12.9.1条第一款第（八）项规 定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一）董事会会议的召开、审议和表决情况 2 经信永中和会计师事务所（特殊普通合伙）审计，截至2024年12月31日， 科美诊断技术股份有限公司（以下简称"公司"）母公司累计未分配利润为人 民币84,925,935.18元，实现归属 ...

证券代码：688468 证券简称：科美诊断 公告编号：2025-008 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科美诊断技术股份有限公司（以下简称"公司"或"科美诊断"）于 2025 年 4 月 27 日召开的第二届董事会第十三次会议与第二届监事会第十二次会议，审议通过 了《关于作废部分已授予尚未归属的限制性股票的议案》，现将有关事项说明如下： 一、本次激励计划已履行的决策程序和信息披露情况 1、2021 年 12 月 27 日，公司召开第一届董事会第十六次会议，审议通过了《关 于公司<2021 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2021 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请股东大会授权董事 会办理公司 2021 年限制性股票激励计划相关事宜的议案》。公司独立董事就本激励 计划相关议案发表了独立意见。 同日，公司召开第一届监事会第十三次会议，审议通过了《关于公司<2021 年限 制性股票激励计划（草案）>及其摘要的议案》《关于公司<2021 年限制性股票激励 计划实施考 ...

上海荣正企业咨询服务（集团）股份有限公司 证券简称：科美诊断 证券代码：688468 关于 科美诊断技术股份有限公司 2021 年限制性股票激励计划 作废部分限制性股票 相关事项 之 独立财务顾问报告 2025 年 4 月 | （二）咨询方式 9 | | --- | 一、释义 1、上市公司、公司、科美诊断：科美诊断技术股份有限公司。 2、股权激励计划、限制性股票激励计划、本激励计划：《科美诊断技术股份有 限公司 2021 年限制性股票激励计划（草案）》。 3、限制性股票、第二类限制性股票：符合激励计划授予条件的激励对象在满足 相应的获益条件后分次获得并登记的公司 A 股普通股股票。 4、股本总额：公司股东大会审议通过本计划时公司已发行的股本总额。 5、激励对象：按照本激励计划规定，有资格获得限制性股票的公司（含子公司） 员工。 6、授予日：公司向激励对象授予限制性股票的日期。 7、授予价格：公司授予激励对象每一股限制性股票的价格。 8、有效期：从限制性股票授予之日起到激励对象获授的限制性股票全部归属或 作废失效的期间。 9、归属：激励对象满足获益条件后，上市公司将股票登记至激励对象账户的行 为。 10、归属条 ...

上海市通力律师事务所 关于科美诊断技术股份有限公司 2021 年限制性股票激励计划作废部分已授予尚未归属的限制性 股票相关事项之法律意见书 致:科美诊断技术股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受科美诊断技术股份有限公司(以下简称"公 司")委托,指派朱晓明律师、黄雅程律师(以下合称"本所律师")作为公司特聘专项法律顾 问,就公司 2021 年限制性股票激励计划(以下简称"本次激励计划")作废部分已授予尚未 归属的限制性股票(以下简称"本次作废")相关事项,根据《中华人民共和国公司法》(以下 简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股权激 励管理办法》(以下简称"《管理办法》")、《上海证券交易所科创板股票上市规则》(以下简 称"《上市规则》")和《科创板上市公司自律监管指南第4号 -- 股权激励信息披露》(以下 简称"《股权激励信息披露自律监管指南》")等法律、行政法规和其他规范性文件(以下简称 "法律、法规和规范性文件")和《科美诊断技术股份有限公司章程》的有关规定,就公司本 次作废事项出具本法律意见书。 为出具本法律意见书,本所律师已 ...

Financial Performance - The company's operating revenue for 2024 was CNY 436,289,767.28, a decrease of 2.03% compared to CNY 445,340,815.75 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 127,074,717.39, down 13.77% from CNY 147,373,517.73 in 2023[22]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 100,730,232.14, a decrease of 16.97% compared to CNY 121,317,262.48 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY 167,950,046.11, down 2.95% from CNY 173,053,196.46 in 2023[22]. - The total assets at the end of 2024 were CNY 1,832,158,296.89, an increase of 0.64% from CNY 1,820,562,566.47 at the end of 2023[22]. - The net assets attributable to shareholders at the end of 2024 were CNY 1,416,307,137.37, an increase of 1.98% from CNY 1,388,801,768.59 at the end of 2023[22]. - The basic earnings per share for 2024 were CNY 0.32, a decrease of 13.51% from CNY 0.37 in 2023[23]. - The diluted earnings per share for 2024 were CNY 0.32, reflecting the same decrease of 13.51% compared to CNY 0.37 in 2023[23]. Dividend Distribution - The proposed cash dividend distribution is 1.25 RMB per 10 shares, totaling approximately 49.32 million RMB, which represents 38.82% of the net profit attributable to shareholders for 2024[5]. - The company is currently not planning to increase capital reserves or issue bonus shares[5]. Research and Development - The R&D investment as a percentage of operating revenue for 2024 was 17.71%, down 1.07 percentage points from 18.78% in 2023[23]. - The company has established a strong foundation for its second growth curve by increasing R&D investment and developing new technologies[34]. - The company has developed advanced marker detection technologies for infectious diseases, including next-generation HIV antigen/antibody detection technology and HCV antigen/antibody combined detection technology[60]. - The company has a research and development team of 172 people, accounting for 27.34% of total employees, with R&D investment representing 17.71% of revenue[81]. - The company has significantly increased its R&D investment, establishing a high-quality research team and advanced facilities to support innovation efforts[199]. Market Strategy - The company is focusing on "import substitution" as a long-term strategy, emphasizing innovation and high-quality development in the medical industry[33]. - The company is actively pursuing import substitution in the high-end medical device market, particularly in the field of chemiluminescence immunodiagnostics, which has significant market opportunities[131]. - The company aims to enhance its diagnostic capabilities for diseases such as diabetes and inflammation through innovative technology and product development[67]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and regulations while protecting shareholder rights[137]. - The board of directors held 5 meetings in 2024 to discuss key issues, ensuring effective governance and decision-making[138]. - The company has implemented robust information disclosure practices to ensure transparency and protect investor interests[138]. - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring clear responsibilities and effective operations[188]. Innovation and Patents - A total of 64 new patents were granted during the reporting period, including 33 domestic invention patents, showcasing the company's growing innovation capability[36]. - The company has obtained 316 authorized patents, including 131 invention patents, as of December 31, 2024[80]. - The company has developed the LiCA® series clinical diagnostic products, which are competitive with international brands like Roche and Abbott[198]. Operational Efficiency - The company has implemented a salary and welfare budget management system to optimize personnel structure and improve efficiency[165]. - The company has established a comprehensive internal control system that is effectively implemented, ensuring no significant omissions in its operations[185]. - The company has established a multi-level training platform to enhance both organizational and individual employee capabilities[166]. Risks and Challenges - The company faces risks related to new product development, which typically takes 3-5 years from project initiation to registration[86]. - The company faces risks related to intensified market competition, particularly from multinational companies and domestic competitors[91]. - There is a risk of declining gross profit margins due to national centralized procurement policies and rising operational costs[93]. Financial Management - The company plans to apply for a comprehensive bank credit line for 2024, as approved in the annual general meeting[141]. - The company will use idle raised funds for cash management as part of its financial strategy[155]. - The company reported a significant increase in revenue, achieving a total of 31.42% share control through indirect holdings by its chairman, Li Lin[147].

Financial Performance - The company's operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27.01% compared to ¥111,390,688.04 in the same period last year[4] - Net profit attributable to shareholders was ¥14,542,813.84, down 62.12% from ¥38,392,507.40 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥11,131,421.96, reflecting a decline of 68.00% compared to ¥34,787,360.92 in the previous year[4] - Basic and diluted earnings per share were both ¥0.04, a decrease of 60.00% from ¥0.10 in the same period last year[4] - Total operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27% compared to ¥111,390,688.04 in Q1 2024[18] - Net profit for Q1 2025 was ¥14,542,813.84, a decline of 62% from ¥38,392,507.40 in Q1 2024[19] - Earnings per share for Q1 2025 was ¥0.04, compared to ¥0.10 in Q1 2024, indicating a 60% decrease[19] - Cash received from sales of goods and services in Q1 2025 was ¥90,331,179.04, down 30% from ¥129,981,796.53 in Q1 2024[21] Cash Flow and Assets - The net cash flow from operating activities decreased by 59.74%, amounting to ¥15,204,001.57, down from ¥37,767,684.23[4] - Total assets at the end of the reporting period were ¥1,815,591,513.49, a decrease of 0.90% from ¥1,832,158,296.89 at the end of the previous year[5] - As of March 31, 2025, the company's total current assets amounted to RMB 1,049,855,808.49, a decrease from RMB 1,067,681,904.23 as of December 31, 2024, reflecting a decline of approximately 1.14%[13] - The company's cash and cash equivalents stood at RMB 401,225,526.99, slightly increasing from RMB 400,252,111.81 in the previous period[13] - Total cash inflow from investment activities was $464,799,073.09, down from $503,609,819.16, resulting in a net cash outflow of $51,537,903.44 compared to a net inflow of $60,935,030.35 previously[22] - The ending balance of cash and cash equivalents was $106,768,979.00, significantly lower than $277,035,240.30 at the end of the previous period[23] Liabilities and Equity - Total liabilities decreased to ¥384,741,562.28 from ¥415,851,159.52, representing a reduction of approximately 7.5%[15] - Non-current liabilities totaled ¥237,393,000.93, a slight increase from ¥232,502,428.90[15] - The company reported a decrease in accounts payable from ¥66,627,322.85 to ¥36,201,224.37, a reduction of about 46%[15] - Shareholders' equity attributable to shareholders was ¥1,430,849,951.21, an increase of 1.03% from ¥1,416,307,137.37 at the end of the previous year[5] Research and Development - Research and development expenses totaled ¥17,156,877.91, a decrease of 14.62% from ¥20,095,592.77 year-on-year[4] - The proportion of R&D expenses to operating revenue increased to 21.10%, up 3.06 percentage points from 18.04%[5] - The company is focusing on R&D investments to enhance technology and product innovation, aiming to meet unmet clinical needs and drive import substitution[12] - The company has established a dual-driven strategy focusing on import substitution and clinical interactive innovation to enhance its product pipeline[12] - The company has a robust product pipeline prepared in advance to navigate industry challenges and aims to create a "new quality productivity" for long-term growth[12] Non-Recurring Gains and Other Income - The company reported non-recurring gains totaling ¥3,411,391.88, primarily due to various non-operating income sources[7] Shareholder Information - The top ten shareholders include Ningbo Baoshui District Yingweili Enterprise Management Partnership with 108,000,008 shares, representing a significant stake in the company[11]

4月28日，科美诊断今日收盘6.93元，下跌1.56%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.89倍，总市值27.80亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.40倍，行业中值34.81倍，科美诊断排 名第51位。 截至2025年一季报，共有9家机构持仓科美诊断，其中其他9家，合计持股数20628.76万股，持股市值 15.37亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)51科美诊断21.8921.871.9427.80亿行业平均 46.4044.004.49100.23亿行业中值34.8134.782.2645.22亿1硕世生物-1850.69-1850.691.1437.05亿2天益医 疗-1581.08-2708.221.6920.15亿3澳华内镜-525.57263.604.2155.39亿4诺唯赞-508.22-508.222.3391.96亿5康 泰医学-256. ...

4月16日，科美诊断今日收盘6.85元，下跌1.58%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.64倍，总市值27.48亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.94倍，行业中值29.64倍，科美诊断排 名第50位。 来源：金融界 科美诊断技术股份有限公司从事临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售，公司产品 为基于光激化学发光法的LiCA系列诊断试剂和基于酶促化学发光法的CC系列诊断试剂及仪器。是国内 最早专业从事临床免疫诊断中化学发光产品开发的专业化高科技企业之一。科美诊断荣获2022年北京市 知识产权示范单位、2022年度第二批北京市市级企业技术中心等荣誉称号。 最新一期业绩显示，2024年三季报，公司实现营业收入3.44亿元，同比-0.43%；净利润1.12亿元，同 比-6.73%，销售毛利率76.35%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)50科美诊断21.6421.641.9627.48亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56- ...

科美诊断2月28日大宗交易平台出现一笔成交，成交量60.00万股，成交金额459.60万元，大宗交易成交 价为7.66元，相对今日收盘价折价1.16%。该笔交易的买方营业部为机构专用，卖方营业部为中信证券 股份有限公司北京紫竹院路证券营业部。 两融数据显示，该股最新融资余额为1.78亿元，近5日增加3421.30万元，增幅为23.86%。（数据宝） 进一步统计，近3个月内该股累计发生17笔大宗交易，合计成交金额为6518.95万元。 2月28日科美诊断大宗交易一览 证券时报•数据宝统计显示，科美诊断今日收盘价为7.75元，下跌3.61%，日换手率为2.46%，成交额为 7778.51万元，全天主力资金净流出544.66万元，近5日该股累计下跌7.96%，近5日资金合计净流出 4187.62万元。 ...